Castle Biosciences Inc. (CSTL) exhibits 79.4% gross margins and -9.3% return on invested capital within Health Care (Medical Specialities), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 79.4% gross profitability converts into -12.4% operating margin and -9.3% ROIC, outpacing sector cost of capital.
ROIC: -9.3% // GM: 79.4%YoY revenue trajectory of +3.7% paired with 2.41% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +3.7% // FCF YLD: 2.41%Altman Z-Score of 6.97 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 6.97 // F-SCORE: 6/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $38.51 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medical Specialities require continuous execution to defend -7.0% net margins.
NET MARGIN: -7.0% // D/E: 0.02x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CSTL & activate live FRED threshold breach alerts.